AbbVie shares are trading higher after the company announced that it will acquire Apogee Therapeutics for $10.9 billion to expand its immunology portfolio.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!